clinIT AG Awarded Federal Grant
Federal Grant for Expert System for Automatic Analysis of Data Quality in Clinical Trials Awarded to Freiburg Partnership
(Freiburg, Germany) In the framework of the development scheme ‘Central Innovation Scheme for Medium-sized Businesses’* of the German Federal Ministry for Economics and Technology (BMWI), clinIT AG, based in Freiburg, Germany, has been awarded a six-figure federal grant in cooperation with the Institute for Informatics of the Albert-Ludwigs-University Freiburg, Faculty for Data Bases and Information Systems.
The IT company, clinIT, intends to develop a novel tool for automatic analysis of data quality in all types of clinical studies. Up to now, such analyses had to be carried out individually for each project via the application programming. On the basis of rules, this new tool will formalize this process and make automatic processing accessible.
For the first time now, this innovation will give project and data managers with no specific programming skills the means to measure and control the quality of data and processes over large-volume study libraries/data bases. The data quality is crucial in a clinical trial, in order to be able to reach accurate and reliable conclusions on the safety and efficacy of the test medication. The new development of clinIT and the Freiburg Institute for Informatics represents not only a decisive advance from the perspective of cost-effectiveness, but especially also in terms of the patient’s well-being.
clinIT AG
Founded in 2001, clinIT AG is a specialist for clinical information technology whose core business is the development and supply of information systems for both data entry and management of clinical trial data as well as providing support for the process flow in clinical studies. The latter involves systems for data capture, patient randomization and disease management. Further services include statistics, data management and medical consulting.
Institute for Informatics of the Albert-Ludwigs-University Freiburg, Faculty for Data Bases and Information Systems
The Institute for Informatics was founded in 1995 and belongs to the Faculty of Applied Sciences of the University. The Faculty for Data Bases and Information Systems has special expertise in the sector of rule-based languages, work flow management systems and internet-based technologies, especially information extraction and integration. Current research projects concern also memory systems for the semantic web and the analysis of correspondingly based query languages.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
